- How is a cancer of unknown primary treated?
- Surgery for cancer of unknown primary
- Radiation therapy for cancer of unknown primary
- Chemotherapy for cancer of unknown primary
- Hormone therapy for cancer of unknown primary
- Targeted therapy for cancer of unknown primary
- Other drugs for cancer of unknown primary
- Clinical trials for cancer of unknown primary
- Complementary and alternative therapies for cancer of unknown primary
- Treatment of specific instances of a cancer of unknown primary
- Palliative care for cancer of unknown primary
- More treatment information
Other drugs for cancer of unknown primary
Bisphosphonates are drugs that are used to help strengthen and reduce the risk of fractures in bones that have been weakened by metastatic cancer. Examples include pamidronate (Aredia®) and zoledronic acid (Zometa®). They are given intravenously (IV). To treat cancer that has spread to bone, they are given once a month.
Bisphosphonates can have side effects, including flu-like symptoms and bone pain. They can also cause kidney problems, so people with kidney problems can’t use them. A rare but very distressing side effect of intravenous bisphosphonates is damage (osteonecrosis) in the jaw bones (ONJ). It can be triggered by having a tooth extraction (removal) while getting treated with the bisphosphonate. ONJ often appears as an open sore in the jaw that won’t heal. It can lead to loss of teeth or infections of the jaw bone. Doctors don’t know why this happens or how to treat it, other than to stop the bisphosphonates. Maintaining good oral hygiene by flossing, brushing, making sure that dentures fit properly, and having regular dental check-ups may help prevent this. Most doctors recommend that patients have a dental check-up and have any tooth or jaw problems treated before they start taking a bisphosphonate.
Like bisphosphonates, denosumab (Prolia®, Xgeva®) is a drug that can be used to strengthen bones and lower the risk of fractures in bones weakened by cancer spread. To treat cancer that has spread to bone, this drug is given as an injection under the skin, once a month.
Side effects include low levels of calcium and phosphate and ONJ. This drug does not cause kidney damage, so it is safe to give to people with kidney problems.
Octreotide (Sandostatin®) is an agent chemically related to a natural hormone, somatostatin. It’s very helpful for some patients with neuroendocrine tumors. If the tumor releases hormones into the bloodstream (which is rare in the poorly differentiated tumors that cause cancer of unknown primary), this drug can stop the hormone release. It can also cause tumors to stop growing or (rarely) to shrink. This drug is available as a short-acting version given as injection 2 to 4 times a day. It’s also available as a long-acting injection that needs to be given only once a month. A similar drug, lanreotide (Somatuline®), is also available. It’s also given as an injection once a month. These drugs are most likely to help treat cancers that show up on somatostatin receptor scintigraphy (OctreoScan).
Last Medical Review: 03/12/2013
Last Revised: 01/31/2014